Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05104359 · ClinicalTrials.gov registry record
COVID-19 Quantitative Antibody Titers & Booster Vaccinations
A clinical trial of COVID-19 and COVID-19 Vaccines, sponsored by Epividian.
- Completed
- Registry status
- 825
- Enrollment target
- 1
- Study location
NCT05104359: Completed study of COVID-19 and COVID-19 Vaccines, sponsored by Epividian.
NCT05104359 is a study of COVID-19 and COVID-19 Vaccines that has completed, run by Epividian. The registered enrollment target is 825 participants, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05104359, a study of COVID-19 and COVID-19 Vaccines, has completed, sponsored by Epividian.
- COMPLETED
- Registry status
- 825 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study aiming at describing COVID-19 vaccination outcomes among HIV-positive and HIV-negative individuals, using electronic health records to observe their usual clinical care. This study will describe levels of COVID-19 vaccine response (i.e., Ig spike antibody measurements). Rates of antibody level decay after vaccination will be assessed. The efficacy of using antibody levels to help guide the timing of booster doses among HIV-negative and HIV-positive patients will be evaluated.
Primary Outcome
Levels of Roche SARS-CoV-2 Semi-Quant Spike Ig antibody
Conditions Studied
Interventions
- OTHER Observational
Study Locations (1)
New York
- AHD Manhattan Midtown HCC - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 825 participants |
| Start Date | 2020-12-11 |
| Est. Completion | 2022-04-30 |
What the finished NCT05104359 record still lists
NCT05104359 is an observational study that tracks outcomes without assigning an intervention. The registered 825 participants enrollment target is mid-sized for trials with a published cap, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT05104359 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05104359 about?
NCT05104359 is a clinical study titled "COVID-19 Quantitative Antibody Titers & Booster Vaccinations". This is an observational study aiming at describing COVID-19 vaccination outcomes among HIV-positive and HIV-negative individuals, using electronic health records to observe their usual clinical care. This study will describe levels of COVID-19 vaccine response (i.e., Ig spike antibody measurements)...
What is the current status of trial NCT05104359?
This trial is currently completed. The enrollment target is 825 participants. The study started on 2020-12-11. Estimated completion is 2022-04-30.
What conditions does trial NCT05104359 study?
This clinical trial studies the following conditions: COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine.
What interventions are being tested in trial NCT05104359?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT05104359?
This trial is sponsored by Epividian, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05104359 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05104359's enrollment target sits among peer trials
825 86th of 298 higher than 213 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05630482 · 825 participants · NA
Randomized Trial of Healthy Family Foundations
- NCT06097728 · 825 participants · Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- NCT07102641 · 825 participants · Phase 4
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
- NCT07318077 · 825 participants · NA
Radicle GI Health DBG: A Study Assessing the Impact of Health and Wellness Products on GI Health and Related Health Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI